Growth + buyout (up to $200M fund research profile
ChrysCapital is an India-focused growth and control investor founded in 1999, with a concentrated sector playbook across technology, financial services, healthcare, consumer and manufacturing. It has built a long operating history around value creation and exits rather than a broad multi-strategy platform.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
ChrysCapital uses a growth + buyout (up to $200m/deal) approach across Fin services, health, pharma, consumer.
Current evidence
ChrysCapital announced the final close of Fund X at $2.2 billion in 2025, describing it as the largest India-focused private-equity fund to date; its current portfolio page names companies including WOW Skin Science, Lenskart, MoEngage, Mphasis, KPIT, Infogain, Hexaware, Safex Chemicals, GMM Pfaudler, FirstCry, Dream Sports and Awfis.
Strategy
Growth + buyout (up to $200M/deal)
Sector focus
Fin services, health, pharma, consumer
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
ChrysCapital announced the final close of Fund X at $2.2 billion in 2025, describing it as the largest India-focused private-equity fund to date; its current portfolio page names companies including WOW Skin Science, Lenskart, MoEngage, Mphasis, KPIT, Infogain, Hexaware, Safex Chemicals, GMM Pfaudler, FirstCry, Dream Sports and Awfis.
Investor questions
ChrysCapital is covered in Rupeia's private equity research universe. The current public record describes the strategy as Growth + buyout (up to $200M/deal), with a sector focus of Fin services, health, pharma, consumer. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to ChrysCapital in the reviewed public sources: Mankind Pharma, NSE, Intas, Infogain, Lenskart, MoEngage, Mphasis, KIMS Hospitals, FirstCry, Dream Sports. It does not represent a complete current portfolio unless the manager has published one.
ChrysCapital reports roughly $7B realised across about 80 exits. Its site cites 42% IRR / 6.5x on Infogain and 40% IRR / 3.8x on LiquidHub; these are deal-level outcomes, not a substitute for audited fund-level performance. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: The manager says it has raised $5B across nine funds and reports Fund IX at $1.25B; the current record also contains a 2025 Fund X close claim that should be read against the cited reporting.. Public terms or access information: Growth and control investments, generally in established Indian businesses; the manager’s public materials do not provide a uniform current cheque, reserve or ownership range across all funds.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Kunal Shroff, Sanjiv Kaul, Gaurav Ahuja. Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: Fund-level deployment and independent verification of historical return claims remain open..
2025: ChrysCapital announced the final close of Fund X at $2.2 billion in 2025, describing it as the largest India-focused private-equity fund to date; its current portfolio page names companies including WOW Skin Science, Lenskart, MoEngage, Mphasis, KPIT, Infogain, Hexaware, Safex Chemicals, GMM Pfaudler, FirstCry, Dream Sports and Awfis.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.